Harvard Bioscience (HBIO) Change in Accured Expenses (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Change in Accured Expenses data on file, last reported at $1.2 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $1.2 million, down 19.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (up 185.42% YoY), and the FY2025 annual result was $2.3 million, up 228.85% from the prior year.
• Change in Accured Expenses improved to $1.2 million in Q1 2026 per HBIO's latest filing, from $797000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.7 million in Q1 2022 and troughed at -$3.2 million in Q2 2022.
• A 5-year average of -$13294.1 and a median of -$14000.0 in 2024 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 660.16% in 2024 and fell as far as 2555.32% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at $980000.0 in 2022, then tumbled by 122.96% to -$225000.0 in 2023, then plunged by 567.56% to -$1.5 million in 2024, then surged by 153.06% to $797000.0 in 2025, then soared by 48.18% to $1.2 million in 2026.
• Business Quant data shows HBIO's Change in Accured Expenses at $1.2 million in Q1 2026, $797000.0 in Q4 2025, and -$271000.0 in Q3 2025.